ReviewRSC advances2021
Recent advances of N-heterocyclic carbenes in the applications of constructing carbo- and heterocyclic frameworks with potential biological activity.
Review in RSC advances, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Facile Synthesis of Indole-, Pyrazole-, and Indazole-Pyrrolidine Hybrids as Novel Chiral Heterocyclic Building Blocks.Molecules (Basel, Switzerland) · 2026Article
- Synthesis ofACS omega · 2026Article
- A Brønsted-based deep eutectic solvent as a green catalyst for the sustainable one-pot synthesis of 1,2,4,5-tetrasubstituted imidazole derivatives:RSC advances · 2026Article
- Metabolomic profiling of Bacillus amyloliquefaciens MU-10 and its antagonistic effects on Cercospora arachidicola.BMC microbiology · 2026Article
- Recent advances in non-conventional synthesis of N-heterocyclic compounds: emerging strategies and biological perspectives.RSC advances · 2025Review
- Heterocycles in Medicinal Chemistry II.Molecules (Basel, Switzerland) · 2024Article
- Article
- Recent Advances in the Green Synthesis of ActivePharmaceuticals (Basel, Switzerland) · 2023Review
- Synthesis and Evaluation of Antiproliferative Activity, Topoisomerase IIα Inhibition, DNA Binding and Non-Clinical Toxicity of New Acridine-Thiosemicarbazone Derivatives.Pharmaceuticals (Basel, Switzerland) · 2022Article
- Construction of multi-substituted pyrazolesRSC advances · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In recent years, N-heterocyclic carbenes (NHCs) have established themselves as a masterful and promising type of organocatalyst for the speedy construction of medicinally and biologically significant molecules from common and accessible small molecules. In particular, various cyclic scaffolds, including carbocycles and heterocycles, have been synthesized using NHCs
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.